News | November 09, 2023
Bayer posts Q3 2023 Group sales Euro 10.34 billion
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
The complexity of operating on a one-year-old are many with the organs being tiny, fragile
Alleviating staff shortages by empowering surgeons with greater personalization and control
Subscribe To Our Newsletter & Stay Updated
